| CEO: | Jeremy Skillington |
| CFO: | Ian O’Connel |
| Executive Chairman: | Cathal Friel |
| Independent Non-Executive Director: | Edward Gibson |
| Independent Non-Executive Director: | Luke O’Neill |
| Independent Non-Executive Director: | Brendan Buckley |
| Non-Executive Dir: |
| Address: | 40 Bank Street, Floor 24, London, United Kingdom, E14 5NR |
| Phone: | +44 (0)20 7183 1499 |
| Website: | http://www.poolbegpharma.com/ |
| Sector: | Pharma and Biotech(LSE) |
| Index: | FTSE AIM All-Share |
| ISIN: | GB00BKPG7Z60 |
| Currency | UK Pounds |
| Share Price | 3.75p |
| Change Today | -0.100p |
| % Change | -2.60 % |
| 52 Week High | 9.10 |
| 52 Week Low | 2.40 |
| Volume | 489,648 |
| Shares Issued | 697.20m |
| Market Cap | £26.15m |
| Beta | 0.93 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth | ![]() |
|---|
| No dividends found |
| Time | Volume / Share Price |
| 16:36 | 17,500 @ 3.75p |
| 15:30 | 1,656 @ 3.72p |
| 15:26 | 165 @ 3.70p |
| 15:05 | 304 @ 3.75p |
| 15:02 | 22,524 @ 3.75p |
| CEO | Jeremy Skillington |
| CFO | Ian O’Connel |
You are here: research